Transcript Slide 1
Stephen Cohn, MD, FACS, UTHSC-SA
SELECTING RESEARCH
PRIORITIES AND STUDIES
NTI Science Committee
Subject matter experts
Senior leadership
In-depth knowledge/awareness of prior
and current trauma research
Members:
Peggy Knudson, MD, Chair
Ellen J. MacKenzie, PhD
David B. Hoyt, MD, Vice-Chair
Andrew B. Peitzman, MD
Timothy C. Fabian, MD
Basil A. Pruitt, Jr., MD
Donald H. Jenkins, MD
Ronald M. Stewart, MD
Gregory J. Jurkovich, MD
Science Committee Role
Determines priorities for each RFP, which is then
broadly distributed
Reviews pre-proposals and issues invitations for full
proposals
Evaluates proposals, makes proposal selections,
and recommends awards and funding decisions to
the Board
The Board, which includes representatives of Army,
Air Force, and Navy, considers recommendations
for full approval
3
Review Criteria
Scientific merit
Clinical relevance
Clinical impact
Innovation
Feasibility of completing study on time
Military relevance
Appropriate budget
Potential for follow-on studies
Multicenter involvement
Proposals and Awards
April, 2010
85 pre-proposals from 25 states plus DC
15 invitations for full proposals
7 awarded studies, with 22 participating sites
January, 2011
92 pre-proposals from 25 states
21 invitations for full proposals
8 awarded studies, with 20 participating sites
5
Pre-proposal Response
Award Distribution
16 Lead Sites
42 Participating Sites
NTI Awarded Studies
$3.8 million
Mycoplasma Pneumoniae in the ICU
Dr. Joel Baseman, University of Texas Health Science Center at San Antonio
Timing and Mechanism of Traumatic Coagulopathy
Dr. Mitchell Cohen, University of California at San Francisco
Evaluation of Ventilator Bundle in Injured Patients
Dr. Martin Croce, University of Tennessee Health Science Center at Memphis
Comparative Effectiveness of Clinical Care Processes in
Resuscitation and Management of Moderate to Severe
Traumatic Injuries
Dr. Shahid Shafi, Baylor Research Institute
Comparison of IV Iron Supplementation to both Enteral
Supplementation and Placebo for the Anemia of Traumatic
Critical Illness
Dr. Fred Pieracci, University of Colorado at Denver
8
Vasopressin Supplementation during Resuscitation of
Hemorrhagic Shock
Dr. Carrie Sims, University of Pennsylvania
Characterization of the effects of the early Sex-Hormone
Environment Following Injury
Dr. Jason Sperry, University of Pittsburgh
The Safety and Efficacy of Platelet Transfusion in Patients
Receiving Antiplatelet Therapy that Sustain Intracranial
Hemorrhage
Mark Cipolle, Christiana Health Care System, Newark DE
Effect of Antioxidant Vitamins on Coagulopathy and
Nosocomial Pneumonia after Severe Trauma
Jean-Francois Pittet, University of Alabama at Birmingham
Detection and Management of Non-Compressible
Hemorrhage by Vena Cava Ultrasonography
Jay J Doucet, University of California San Diego
9
Splenic Injury Prospective Outcomes Trial
Ben Zarzaur, AAST/ PI: University of Tennessee Health Science Center,
Memphis TN
Transfusion of Stored Fresh Whole Blood in a Civilian Trauma
Center: A Prospective Evaluation of Feasibility and
Outcomes
Gill Cryer, UCLA Dept of Surgery, Los Angeles, CA
Acute Lung Injury Ventilation Evaluation (ALIVE) Trial
Suresh Agarwal, Boston Medical Center, Boston, MA
Methicillin-Resistant Staphylococcus aureus in a Trauma
Population: Does Decolonization Prevent Infection?
Robert Maxwell, Univ. of Tenn. HSC, Chattanooga, TN
Thrombelastography (TEG®) based dosing of enoxaparin for
thromboprophylaxis: a prospective randomized trial
Martin A Schreiber, Oregon Health & Science University, Portland, OR
Hepcidin and Anemia in Trauma
Lena M. Napolitano, Univ. of Michigan Health System, Ann Arbor MI
Research Project Awards:
NTI Role/Responsibilities
Manages RFP and review process
Manages regulatory compliance through TATRC,
HRPO, and USAMRMC
Manages contracts
Monitors scientific progress and prepares reports
Holds annual investigator meeting
Sponsors annual trauma conference to disseminate
results, encourage investigators, and support
military/civilian exchange
11
Timing and Mechanism of Traumatic Coagulopathy
Wireless Vital Sign Monitor Project
Mycoplasma Pneumoniae in the ICU
SELECT NTI FUNDED STUDIES
Stephen Cohn, MD, FACS, UTHSC-SA
MYCOPLASMA PNEUMONIAE IN
THE ICU
Mycoplasma Pneumoniae in the ICU
Preliminary data showed M. pneumoniae
common in ICU patients with suspected VAP
associated with prolonged ventilator course
associated with poor oxygenation in subjects with
ARDS
14
Mycoplasma Pneumoniae in the ICU
Multicenter, prospective, observational study
Investigating the role of Mycoplasma
pneumoniae in ICU patients with suspected
ventilator-associated pneumonia (VAP)
Objectives are to:
determine the incidence of M. pneumoniae infection
among critically ill ventilator-dependent subjects
evaluate the impact of this pathogen on ICU
outcomes
15
Mycoplasma Pneumoniae in the ICU
Apply novel diagnostic assays targeting the Community
Acquired Respiratory Distress Syndrome (CARDS) toxin
Subjects undergo routine bronchoscopy with
bronchoalveolar lavage (BAL) for the diagnosis of VAP
Samples of BAL fluid and serum collected
Polymerase chain reaction (PCR) assessment for CARDS
toxin gene sequences
BAL tested for CARDS toxin protein
Serum assayed for anti-CARDS toxin antibodies
Additional serum samples collected to test for
seroconversion
16
Mycoplasma Pneumoniae in the ICU
Research will:
Determine the incidence of M. pneumoniae
Determine the ventilator course and ICU outcomes
Determine the physiologic implications of M.
pneumoniae in this setting
Expand upon preliminary findings from a single
hospital
17
Mycoplasma Pneumoniae in the ICU
First study to employ these novel assays for the
rapid detection of M. pneumoniae infection in
the ICU
First study to systematically evaluate the
contribution of this pathogen to pulmonary
dysfunction in critically ill subjects.
18